Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$24.05 +0.7%	$21.93	$12.21 ▼ $41.31	$697.77M	-0.27	643,024 shs	212,764 shs
MRSN Mersana Therapeutics	$0.29 +3.7%	$0.35	$0.26 ▼ $2.83	$36.08M	0.79	2.72 million shs	1.86 million shs
OGI Organigram Global	$1.42 +2.9%	$1.31	$0.85 ▼ $2.08	$191.53M	1.36	659,440 shs	546,098 shs
PGNX Progenics Pharmaceuticals	$4.10	$4.10	$1.89 ▼ $6.37	$355.05M	1.89	1.16 million shs	34.93 million shs
PRQR ProQR Therapeutics	$2.14 +0.6%	$1.81	$1.07 ▼ $4.62	$229.36M	0.36	659,483 shs	175,653 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+7.01%	+13.05%	+29.90%	-3.43%
MRSN Mersana Therapeutics	0.00%	-0.34%	-21.41%	-4.26%	-84.24%
OGI Organigram Global	0.00%	+5.19%	+5.97%	+49.38%	-10.69%
PGNX Progenics Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PRQR ProQR Therapeutics	0.00%	+5.05%	+18.40%	+81.61%	+30.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	2.3136 of 5 stars	3.4	1.0	0.0	0.0	2.2	2.5	0.6
MRSN Mersana Therapeutics	3.6885 of 5 stars	3.5	1.0	0.0	4.1	1.4	2.5	0.0
OGI Organigram Global	0.6522 of 5 stars	0.0	1.0	0.0	0.0	1.1	0.0	2.5
PGNX Progenics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	2.1478 of 5 stars	3.6	3.0	0.0	0.0	2.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	76.23% Upside
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,693.10% Upside
OGI Organigram Global	3.00	Buy	N/A	N/A
PGNX Progenics Pharmaceuticals	0.00	N/A	N/A	N/A
PRQR ProQR Therapeutics	3.13	Buy	$8.00	273.31% Upside

Current Analyst Ratings Breakdown

Latest ANAB, MRSN, PGNX, OGI, and PRQR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$91.28M	7.74	N/A	N/A	$2.33 per share	10.32
MRSN Mersana Therapeutics	$40.50M	0.89	N/A	N/A	($0.08) per share	-3.63
OGI Organigram Global	$117.47M	1.62	N/A	N/A	$2.07 per share	0.69
PGNX Progenics Pharmaceuticals	$34.99M	10.15	N/A	N/A	$0.54 per share	7.59
PRQR ProQR Therapeutics	$20.46M	11.02	N/A	N/A	$0.91 per share	2.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
OGI Organigram Global	-$33.39M	$0.10	0.00	N/A	N/A	8.05%	-5.93%	-4.39%	8/12/2025 (Estimated)
PGNX Progenics Pharmaceuticals	-$68.55M	-$0.80	N/A	N/A	N/A	-180.28%	-129.46%	-53.23%	N/A
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)

Latest ANAB, MRSN, PGNX, OGI, and PRQR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
PGNX Progenics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.25	8.25
MRSN Mersana Therapeutics	N/A	1.83	1.83
OGI Organigram Global	N/A	3.42	1.90
PGNX Progenics Pharmaceuticals	0.99	2.12	2.12
PRQR ProQR Therapeutics	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
MRSN Mersana Therapeutics	93.92%
OGI Organigram Global	34.63%
PGNX Progenics Pharmaceuticals	70.96%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
MRSN Mersana Therapeutics	13.00%
OGI Organigram Global	0.09%
PGNX Progenics Pharmaceuticals	4.26%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
OGI Organigram Global	860	133.94 million	133.82 million	Optionable
PGNX Progenics Pharmaceuticals	79	86.60 million	N/A	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

ANAB, MRSN, PGNX, OGI, and PRQR Headlines

Recent News About These Companies

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3 at 10:39 PM | morningstar.comM

Brokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $8.00

July 3 at 2:21 AM | americanbankingnews.com

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2 at 7:43 PM | morningstar.comM

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Buy" from Brokerages

June 30, 2025 | marketbeat.com

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics (NASDAQ:PRQR) Earns Market Outperform Rating from JMP Securities

June 29, 2025 | americanbankingnews.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP Securities

June 27, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

Cantor Fitzgerald Comments on PRQR FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR)

June 6, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts

June 5, 2025 | marketbeat.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025 | globenewswire.com

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position

May 10, 2025 | nasdaq.com

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
By Leo Miller | June 25, 2025
View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?
By Chris Markoch | June 13, 2025
View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?
Wall Street Sees More Upside for Dell and HPE
By Leo Miller | June 12, 2025
View Wall Street Sees More Upside for Dell and HPE
Geospace Stock Skyrockets After Major Petrobras Contract
By Jeffrey Neal Johnson | June 24, 2025
View Geospace Stock Skyrockets After Major Petrobras Contract
Why Occidental's Price Dip Signals a Buying Opportunity
By Jeffrey Neal Johnson | July 3, 2025
View Why Occidental's Price Dip Signals a Buying Opportunity

ANAB, MRSN, PGNX, OGI, and PRQR Company Descriptions

AnaptysBio NASDAQ:ANAB

$24.04 +0.17 (+0.69%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$23.57 -0.47 (-1.97%)

As of 07/3/2025 04:36 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Mersana Therapeutics NASDAQ:MRSN

$0.29 +0.01 (+3.68%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$0.30 +0.01 (+1.72%)

As of 07/3/2025 04:59 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Organigram Global NASDAQ:OGI

$1.42 +0.04 (+2.90%)

Closing price 07/3/2025 03:34 PM Eastern

Extended Trading

$1.43 +0.01 (+0.70%)

As of 07/3/2025 04:33 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Progenics Pharmaceuticals NASDAQ:PGNX

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

ProQR Therapeutics NASDAQ:PRQR

$2.14 +0.01 (+0.52%)

As of 07/3/2025 03:59 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time